ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Integra LifeSciences Holdings Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action

New York, New York--(Newsfile Corp. - October 26, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Integra LifeSciences Holdings Corporation (NASDAQ: IART) between March 11, 2019 and May 22, 2023, both dates inclusive (the "Class Period"), of the important November 13, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Integra common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Integra class action, go to https://rosenlegal.com/submit-form/?case_id=19078^[1] or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com^[2] or cases@rosenlegal.com^[3] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 13, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period defendants made false statements and/or concealed that Integra had failed to take sufficient measures to remediate the violations identified by the U.S. Food and Drug Administration ("FDA") in the November 2, 2018 Notice of Inspectional Observations on Form 483, the March 6, 2019 FDA issued warning letter, and the November 12, 2021 FDA issued Form 483. As a result of those deficiencies, since March 2018, all products manufactured in the Company's manufacturing plant located in Boston, Massachusetts (the "Boston Facility"), including SurgiMend, PriMatrix, Revize, and TissueMend, had the potential for higher-than-permitted levels of endotoxin and would need to be recalled. Moreover, Integra was not making progress towards obtaining its premarket approval ("PMA") indication for SurgiMend, in part, because the manufacturing site that would produce the PMA product, the Boston Facility, was in continued violation of the FDA standards that Integra failed to rectify years after the initial notice of the violations and as a result the facility had to be shutdown to correct those ongoing deficiencies. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Integra class action, go to https://rosenlegal.com/submit-form/?case_id=19078^[4] or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com^[5] or cases@rosenlegal.com^[6] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm^[7], on Twitter: https://twitter.com/rosen_firm^[8] or on Facebook: https://www.facebook.com/rosenlawfirm/^[9].

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.Phillip Kim, Esq.The Rosen Law Firm, P.A.275 Madison Avenue, 40th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827lrosen@rosenlegal.compkim@rosenlegal.comcases@rosenlegal.comwww.rosenlegal.com^{[10][11][12][13]}

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/185340^[14]

References

1. ^{^} https://rosenlegal.com/submit-form/?case_id=19078 (api.newsfilecorp.com)
2. ^{^} pkim@rosenlegal.com (www.newsfilecorp.com)
3. ^{^} cases@rosenlegal.com (www.newsfilecorp.com)
4. ^{^} https://rosenlegal.com/submit-form/?case_id=19078 (api.newsfilecorp.com)
5. ^{^} pkim@rosenlegal.com (www.newsfilecorp.com)
6. ^{^} cases@rosenlegal.com (www.newsfilecorp.com)
7. ^{^} https://www.linkedin.com/company/the-rosen-law-firm (api.newsfilecorp.com)
8. ^{^} https://twitter.com/rosen_firm (api.newsfilecorp.com)
9. ^{^} https://www.facebook.com/rosenlawfirm/ (api.newsfilecorp.com)
10. ^{^} lrosen@rosenlegal.com (www.newsfilecorp.com)
11. ^{^} pkim@rosenlegal.com (www.newsfilecorp.com)
12. ^{^} cases@rosenlegal.com (www.newsfilecorp.com)
13. ^{^} www.rosenlegal.com (api.newsfilecorp.com)
14. ^{^} https://www.newsfilecorp.com/release/185340 (api.newsfilecorp.com)